The report projects ONGC's revenue to decline 4.6% QoQ due to lower crude and gas realizations, with EBITDA estimated at INR 263.3bn.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
All houses
HDFC Securities
Motilal Oswal
Tata Asset Management
Mirae Asset Sharekhan
India IPO
Jainam
GEPL Capital
Way2Wealth
SBICAP Securities
Angel One
Axis Securities
ICICI Direct Research Retail
Religare
Arete Securities
Formerly known as Way2Wealth
ICICI Direct
Way2Wealth Securities
quant Mutual Fund
ICICI Securities
Kotak Securities
JM Financial
ICICI Securities – Retail
Ventura Securities
Global Markets by Vested
Prabhudas Lilladher
ITC Hotels
Elara Securities
Exterminators PLC
Emkay Global
Industrial Asphalts
Private Client Group Research summarized from KIE research report
Kahawatte Plantations PLC
2527 notes · all time
The note reports APAT delivered 13/29% YoY/QoQ volume growth driven by the higher-margin APL Apollo brand, expects flattish margins QoQ, and maintains its BUY rating and target price.
Read this note →The note expects SAIL to post healthy 7/26% YoY/QoQ volume growth and maintains its ADD rating and target price.
Read this note →The note expects Jindal Steel to deliver strong 25% YoY volume growth from recent expansion ramp-ups, while estimating the largest margin contraction among coverage companies, and maintains its BUY rating and target price.
Read this note →The note expects JSW Steel's sales volume to rise 2/20% YoY/QoQ aided by gradual ramp-up of BF3 at Vijayanagar, and maintains its BUY rating and target price.
Read this note →The note expects Tata Steel to deliver flattish YoY consolidated volumes with India deliveries up 7% YoY offset by declines in EU and Thailand, and maintains its BUY rating and target price.
Read this note →The report estimates a Sales/EBITDA impact of 0.6%/2.7% from the oncology drug price cap and maintains an ADD rating.
Read this note →The report estimates a Sales/EBITDA impact of 1.3%/5.0% from the oncology drug price cap and maintains an ADD rating.
Read this note →The report estimates a Sales/EBITDA impact of 0.5%/2.8% from the oncology drug price cap and maintains a BUY rating.
Read this note →The report states Tata Motors and Stellantis partnered to develop vehicles in India for more than 50 global markets.
Read this note →The report states L&T Technology Services launched an AI-native Engineering Intelligence Lab focused on digital manufacturing and physical AI applications.
Read this note →The report states HCLTech signed a partnership with Anthropic to establish a dedicated AI business unit.
Read this note →The report states CreditAccess Grameen raised $175 million through a syndicated social loan to support lending and financial inclusion initiatives.
Read this note →The report states Emcure Pharmaceuticals approved the merger of its subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals into the parent company as part of corporate restructuring.
Read this note →The report lists Max Healthcare Institute among the top losers, down 2.02-3.15%.
Read this note →The report lists Larsen & Toubro among the top losers, down 2.02-3.15%.
Read this note →The report lists Tech Mahindra among the top losers, down 2.02-3.15%.
Read this note →The report lists ITC among the top losers, down 2.02-3.15%.
Read this note →The report lists Apollo Hospitals Enterprise among the top losers, down 2.02-3.15%.
Read this note →The report lists BSE among the top gainers, up 1.31-2.71%.
Read this note →The report lists Bharat Electronics among the top gainers, up 1.31-2.71%.
Read this note →The report lists Tata Motors Passenger Vehicles among the top gainers, up 1.31-2.71%.
Read this note →The report lists Bajaj Auto among the top gainers, up 1.31-2.71%.
Read this note →The report lists Dr. Reddy's Laboratories among the top gainers, up 1.31-2.71%.
Read this note →The note says Can Fin Homes' Q2FY27 earnings were largely in line with estimates, with a temporary disbursement slowdown due to tech transformation expected to reverse from Q3, while profitability metrics remain strong.
Read this note →